BUND FINANCE

BUND FINANCE › Stocks › GMAB

Genmab A/S (GMAB)

NASDAQ · Stock price, chart and technical analysis

US$50.97-0.9900 (-1.91%)

Data from Financial Modeling Prep · Nov 18, 2026, 4:00 PM New York time · may be delayed

Open the live chartSee Technicals⏱ Analyze entryQuarterly earnings📅 See in calendar💬 Explain this move⇄ ComparePractice in the Simulator

Key stats

Previous closeUS$51.96
OpenUS$51.60
Day rangeUS$50.89 – US$52.26
52-week rangeUS$20.23 – US$59.97
Market capUS$31.43B
Volume2.96M
50-day averageUS$41.88
200-day averageUS$31.73
Beta0.65

Quick technical read

This describes price action; it is not a recommendation. The app also calculates RSI, MACD, the entry setup and 30+ indicators. How we calculate it

Fundamentals Annual

Fiscal year20212022202320242025
RevenueUS$8.4BUS$14.5BUS$16.5BUS$21.5BUS$3.7B
Net incomeUS$3.0BUS$5.5BUS$4.4BUS$7.8BUS$963.8M
EPS (diluted)4.488.266.6012.141.54
Gross margin100.0%100.0%98.6%95.4%91.7%
Operating margin35.1%43.2%32.3%31.1%33.6%
Net margin35.1%37.6%26.4%36.4%25.9%
Free cash flowUS$2.0BUS$3.6BUS$7.0BUS$7.6BUS$1.1B
Total debtUS$425.0MUS$597.0MUS$770.0MUS$1.0BUS$5.4B
CashUS$9.0BUS$9.9BUS$14.9BUS$9.9BUS$1.7B

Compound annual growth: revenue -18.5% · net income -24.4% (4 years).

Valuation: today, its history and its sector

Today5-year averageSector median (Healthcare)
P/E43.6x31.5x27.1x
EV / EBITDA28.8x22.2x16.5x
Operating margin30.6%—3.6%
Net margin17.0%—-0.0%
Debt / equity1.04—0.58

Source: annual financial statements from Financial Modeling Prep. “Today” uses the current price and the last 4 quarters. The sector median uses U.S. companies above US$300M market cap. A multiple above or below its history or sector is not a recommendation.

About Genmab A/S

SectorHealthcare
IndustryBiotechnology
CountryDK
CEOJan van de Winkel
Employees3,244
IPO date2009-06-01

Genmab A/S, a biotechnology firm based in Copenhagen, Denmark, specializes in the discovery and development of innovative antibody-based treatments for various forms of cancer and other serious conditions. The company currently commercializes several key therapeutic antibodies. DARZALEX (daratumumab) is utilized in the treatment of multiple myeloma (MM), specific non-MM blood cancers, and AL amyloidosis. Other marketed offerings include teprotumumab for thyroid eye disease, ofatumumab, which addresses chronic lymphocytic leukemia (CLL) and multiple sclerosis, and Amivantamab for advanced or metastatic non-small cell lung cancer (NSCLC) as well as gastric or esophageal cancers. Genmab maintai…

www.genmab.com

Other stocks on BUND FINANCE

Not financial advice. BUND FINANCE publishes general information for educational purposes. Investing involves risk, including loss of capital. Legal notice